BioNexus Gene Lab Corp. Income (Loss) from Continuing Operations before Income Taxes, Domestic
BioNexus Gene Lab Corp. (BGLC) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$303.66 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2023-03-31
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2022-03-31 was $31.36K, a 90.74% decline year-over-year.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-12-31 was $197.08K.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-09-30 was $370.49K, a 57.69% increase year-over-year.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-06-30 was $136.54K.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$303.66K, a 129.12% decline from fiscal 2021.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was $1.04M, a 17.40% decline from fiscal 2020.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for fiscal 2020 was $1.26M.
- BioNexus Gene Lab Corp. income (loss) from continuing operations before income taxes, domestic for fiscal 2019 was -$275.70K.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$303.66K 10-K · filed 2023-03-31 | |||
| 2022-03-31 | $31.36K 10-Q · filed 2022-05-16 | $228.44K derived: sum of 2 quarters · filed 2023-03-31 | $598.93K derived: sum of 3 quarters · filed 2023-03-31 | $735.48K derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-12-31 | $197.08K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $567.57K derived: sum of 2 quarters · filed 2023-03-31 | $704.11K derived: sum of 3 quarters · filed 2023-03-31 | $1.04M 10-K · filed 2023-03-31 |
| 2021-09-30 | $370.49K 10-Q · filed 2021-11-15 | $507.03K derived: sum of 2 quarters · filed 2021-11-15 | $845.78K 10-Q · filed 2021-11-15 | $838.19K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-06-30 | $136.54K 10-Q · filed 2021-08-12 | $475.29K 10-Q · filed 2021-08-12 | $467.69K derived: sum of 3 quarters · filed 2022-05-16 | $702.64K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-03-31 | $338.74K 10-Q · filed 2022-05-16 | $331.15K derived: sum of 2 quarters · filed 2022-05-16 | $566.10K derived: sum of 3 quarters · filed 2022-05-16 | $530.75K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$7.59K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | $227.36K derived: sum of 2 quarters · filed 2022-04-06 | $192.00K derived: sum of 3 quarters · filed 2022-04-06 | $1.26M 10-K · filed 2022-04-06 |
| 2020-09-30 | $234.95K 10-Q · filed 2021-11-15 | $199.60K derived: sum of 2 quarters · filed 2021-11-15 | $1.27M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$35.35K 10-Q · filed 2021-08-12 | $1.04M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.07M 10-Q · filed 2021-05-18 | |||
| 2019-12-31 | -$275.70K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |